Entero Healthcare Solutions Ltd
Incorporated in 2018, Entero Healthcare
Solutions Ltd is in the business of distribution
and marketing of pharmaceutical and surgical products and allied services[1]
- Market Cap ₹ 5,607 Cr.
- Current Price ₹ 1,289
- High / Low ₹ 1,584 / 1,078
- Stock P/E 54.7
- Book Value ₹ 396
- Dividend Yield 0.00 %
- ROCE 8.72 %
- ROE 5.64 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 152% CAGR over last 5 years
Cons
- Stock is trading at 3.25 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|
1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 5,403 | |
1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 5,211 | |
Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 191 |
OPM % | 2% | 1% | 1% | 2% | 3% | 3% | 4% |
5 | 11 | 4 | 6 | 14 | 40 | 32 | |
Interest | 13 | 20 | 29 | 49 | 66 | 42 | 43 |
Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 33 |
Profit before tax | 4 | -11 | -20 | -4 | 36 | 139 | 148 |
Tax % | 67% | 42% | 49% | 201% | -12% | 23% | |
1 | -15 | -29 | -11 | 40 | 107 | 117 | |
EPS in Rs | 93.81 | -1,550.90 | -77.71 | -28.12 | 8.99 | 21.80 | 23.58 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 30% |
3 Years: | 26% |
TTM: | 31% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 152% |
3 Years: | 73% |
TTM: | 94% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 5% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 |
Reserves | -16 | -32 | -62 | -73 | 1,595 | 1,681 |
603 | 720 | 974 | 1,101 | 338 | 385 | |
162 | 147 | 210 | 275 | 369 | 593 | |
Total Liabilities | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 |
186 | 189 | 262 | 268 | 289 | 560 | |
CWIP | 2 | 2 | 1 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 58 |
560 | 645 | 863 | 1,040 | 2,056 | 2,085 | |
Total Assets | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
-37 | -69 | -35 | -45 | -37 | -77 | |
-203 | -31 | -162 | -49 | -704 | 220 | |
217 | 89 | 211 | 73 | 863 | -74 | |
Net Cash Flow | -23 | -11 | 14 | -21 | 122 | 69 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 63 | 50 | 54 | 57 | 57 | 59 |
Inventory Days | 57 | 54 | 49 | 41 | 43 | 52 |
Days Payable | 32 | 22 | 22 | 25 | 24 | 31 |
Cash Conversion Cycle | 88 | 82 | 81 | 73 | 77 | 80 |
Working Capital Days | 57 | 54 | 41 | 32 | 48 | 70 |
ROCE % | 1% | 1% | 5% | 7% | 9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11h - Submission of copy of Newspaper publication of unaudited Financial Results for the quarter ended June 30, 2025
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Investor Presentation on Unaudited Financial Results for the quarter ended June 30, 2025
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
2d - ICRA reports no deviation in Entero's IPO fund usage for Q1 FY2026; Rs. 879.78 Cr utilized, Rs. 71.55 Cr unutilized.
-
Unaudited Financial Results For The Quarter Ended June 30, 2025
2d - Q1 FY26 unaudited financial results and acquisition timeline extension announced by Entero Healthcare.
-
Board Meeting Outcome for Outcome Of Board Meeting
2d - Q1 FY26 unaudited results, acquisition timeline extended, new subsidiaries added, IPO proceeds utilization updated.
Concalls
-
Aug 2025TranscriptNotesPPT
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptNotesPPT
-
Mar 2024Transcript PPT
Business Overview:[1]
EHSL, a leading Healthcare Supply Chain Solutions Specialist, ranks among India’s top three healthcare product distributors by revenue, offering demand fulfillment and generation solutions to manufacturers.